Exelixis
EXEL
#1697
Rank
S$13.38 B
Marketcap
$46.86
Share price
0.52%
Change (1 day)
65.09%
Change (1 year)
Exelixis, Inc. is an American genomics-based drug discovery company and the producer of Cometriq, a treatment for medullary thyroid cancer.

Exelixis (EXEL) - Total assets

Total assets on the balance sheet as of September 2024 : S$3.98 Billion

According to Exelixis's latest financial reports the company's total assets are S$3.98 Billion. A companyโ€™s total assets is the sum of all current and non-current assets, such as inventories, cash and cash equivalents, properties and equipment.

Exelixis - Total assets on balance sheet (from 2001 to 2024)

Total assets by year

Year Total assets Change
2023-12-31S$3.88 B-5.63%
2022-12-31S$4.11 B16.42%
2021-12-31S$3.53 B25.09%
2020-12-31S$2.82 B11.22%
2019-12-31S$2.54 B30.84%
2018-12-31S$1.94 B121.69%
2017-12-31S$0.87 B1.65%
2016-12-31S$0.86 B83.41%
2015-12-31S$0.47 B10.06%
2014-12-31S$0.42 B-33.01%
2013-12-31S$0.63 B-27.69%
2012-12-31S$0.88 B73.15%
2011-12-31S$0.50 B9.59%
2010-12-31S$0.46 B-3.6%
2009-12-31S$0.48 B-16.06%
2008-12-31S$0.57 B-3.15%
2007-12-31S$0.59 B-2.19%
2006-12-31S$0.60 B9.45%
2005-12-31S$0.55 B16.55%
2004-12-31S$0.47 B-21.81%
2003-12-31S$0.60 B3.31%
2002-12-31S$0.58 B-8.3%
2001-12-31S$0.64 B

Total Assets for similar companies or competitors

Company Total assets differencediff. Country
S$104.53 B 2,524.37%๐Ÿ‡ฌ๐Ÿ‡ง UK
S$187.15 B 4,598.71%๐Ÿ‡ซ๐Ÿ‡ท France
S$158.14 B 3,870.30%๐Ÿ‡บ๐Ÿ‡ธ USA
S$126.03 B 3,064.23%๐Ÿ‡บ๐Ÿ‡ธ USA
S$122.28 B 2,970.08%๐Ÿ‡บ๐Ÿ‡ธ USA
S$239.88 B 5,922.64%๐Ÿ‡บ๐Ÿ‡ธ USA
S$295.30 B 7,314.03%๐Ÿ‡บ๐Ÿ‡ธ USA
S$67.83 M-98.30%๐Ÿ‡บ๐Ÿ‡ธ USA
S$0.13 B-96.58%๐Ÿ‡บ๐Ÿ‡ธ USA